Strategies for Treating Autoimmunity

Current treatments for myasthenia gravis (MG) rely upon the administration of immunosuppressive agents which result in global, nonspecific attenuation of the immune response. An alternative approach would be to attempt to design therapies that specifically dampen autoreactivity without affecting general immunity. Recently, dendritic cells (DCs) have been shown to possess potent capabilities to tolerize T cells in an antigen‐specific manner. We have observed that the selective activation of particular subsets of DCs utilizing granulocyte–macrophage colony‐stimulating factor (GM‐CSF) had profound effects on the induction of experimental autoimmune myasthenia gravis (EAMG). Specifically, treatment with GM‐CSF effectively suppressed the induction of EAMG and down‐modulated anti‐AChR T cell and pathogenic antibody responses. These effects were associated with the activation of tolerogenic DCs, the enhanced production of suppressive cytokines, such as IL‐10, and the mobilization of CD4 + CD25 + and FoxP3 + regulatory T cells (Tregs). We have further shown that GM‐CSF effectively ameliorates clinical disease severity in mice with active, ongoing EAMG. Based on these observations, we hypothesize that the selective activation of particular DC subsets in vivo using pharmacologic agents, like GM‐CSF, can suppress ongoing anti‐AChR immune responses by mobilizing antigen‐specific Tregs capable of suppressing autoimmune MG.